Capricor Therapeutics (CAPR) Draws Biotech Investor Interest on Deramiocel FDA Update
Capricor Therapeutics (CAPR) surged as biotech investors priced deramiocel FDA approval probability for Duchenne MD
Key points
- Capricor Therapeutics (CAPR) surged as biotech investors priced deramiocel FDA approval probability for Duchenne MD
- Institutional peer comparisons to AMGN, REGN, GILD, LLY signal M&A option premium in CAPR at current prices
- Watch: deramiocel supplemental data submission timeline, FDA track designation, and 13F institutional ownership changes
What’s your take on this? Join the discussion below.
Read the full analysis on market.news
🇺🇸 United States Stocks Biotech healthcare biotech fda rare-disease